Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 4.75 | 0.00% | 0.00 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| 20 DMA Support | Bullish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| Up 5 Days in a Row | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 3.94% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 15 hours ago |
| Possible NR7 | about 15 hours ago |
| 60 Minute Opening Range Breakout | about 19 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| Up 3% | about 19 hours ago |
Get a Trading Assistant
- Earnings date: 05/07/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Organic Chemistry Chronic Lymphocytic Leukemia Lymphocytic Leukemia Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.52 |
| 52 Week Low | 3.95 |
| Average Volume | 140,160 |
| 200-Day Moving Average | 9.67 |
| 50-Day Moving Average | 5.13 |
| 20-Day Moving Average | 4.51 |
| 10-Day Moving Average | 4.36 |
| Average True Range | 0.37 |
| RSI (14) | 51.92 |
| ADX | 14.52 |
| +DI | 20.93 |
| -DI | 14.40 |
| Chandelier Exit (Long, 3 ATRs) | 4.15 |
| Chandelier Exit (Short, 3 ATRs) | 5.06 |
| Upper Bollinger Bands | 5.06 |
| Lower Bollinger Band | 3.96 |
| Percent B (%b) | 0.72 |
| BandWidth | 24.33 |
| MACD Line | -0.14 |
| MACD Signal Line | -0.22 |
| MACD Histogram | 0.0811 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.08 | ||||
| Resistance 3 (R3) | 5.10 | 5.02 | 5.03 | ||
| Resistance 2 (R2) | 5.02 | 4.93 | 5.01 | 5.01 | |
| Resistance 1 (R1) | 4.88 | 4.88 | 4.84 | 4.86 | 4.99 |
| Pivot Point | 4.80 | 4.80 | 4.78 | 4.79 | 4.80 |
| Support 1 (S1) | 4.66 | 4.71 | 4.62 | 4.64 | 4.51 |
| Support 2 (S2) | 4.58 | 4.66 | 4.57 | 4.49 | |
| Support 3 (S3) | 4.44 | 4.58 | 4.48 | ||
| Support 4 (S4) | 4.42 |
